Totally Joined for Achieving Collaborative Techniques, Atlanta, GA 30303, USA.
Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA.
Int J Environ Res Public Health. 2024 Jun 21;21(7):816. doi: 10.3390/ijerph21070816.
The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) observed significant declines in screening volume early in the COVID-19 pandemic, January-June 2020, with variation by race/ethnicity and geography. We aimed to determine how screening in the NBCCEDP recovered from these early declines as it is important for monitoring the long-term impact on women served by the program.
Extending the previous analyses, we compared monthly breast (BC) and cervical cancer (CVC) screening volume in the NBCCEDP during 2020-2022, to five-year, pre-COVID-19 pandemic averages (2015-2019), and calculated percent change. Results were stratified by race/ethnicity and rurality groups. We employed multiple one-way ANOVA tests, which included multiple comparisons, to test for significant differences between groups.
By December 2022, NBCCEDP breast and cervical cancer screening volumes had not fully recovered to pre-COVID-19 5-year averages, and recovery in breast cancer screening volume was slower than that of cervical cancer. Both BC and CVC screening among women in metro areas showed the smallest average monthly deficits (-8.8% BC and -4.9% CVC) compared to monthly pre-COVID-19 pandemic 5-year averages, and screening among women in rural areas showed the greatest deficits (-37.3% BC and -26.7% CVC). BC and CVC screening among Hispanic women showed the greatest improvements compared to the pre-COVID-19 averages (8.2% BC and 9.5% CVC), and cervical cancer screening among non-Hispanic Asian and Pacific Islander women showed the greatest deficits (-41.4% CVC).
For increased intervention efforts, NBCCEDP recipients can focus on populations demonstrating greatest deficits in screening volume.
国家乳腺癌和宫颈癌早期检测计划(NBCCEDP)观察到,2020 年 1 月至 6 月 COVID-19 大流行早期,筛查量显著下降,且存在种族/民族和地理位置差异。我们旨在确定 NBCCEDP 的筛查工作如何从这些早期下降中恢复过来,因为这对于监测该计划服务的女性的长期影响很重要。
扩展之前的分析,我们比较了 2020 年至 2022 年 NBCCEDP 中每月乳腺癌(BC)和宫颈癌(CVC)筛查量与 COVID-19 大流行前五年(2015-2019 年)的平均水平,并计算了百分比变化。结果按种族/民族和农村地区进行分层。我们采用了多个单向方差分析检验,其中包括多重比较,以检验组间是否存在显著差异。
到 2022 年 12 月,NBCCEDP 的乳腺癌和宫颈癌筛查量尚未完全恢复到 COVID-19 前五年的平均水平,且乳腺癌筛查量的恢复速度慢于宫颈癌。与每月 COVID-19 大流行前五年的平均水平相比,大都市地区女性的 BC 和 CVC 筛查量平均每月降幅最小(-8.8% BC 和-4.9% CVC),农村地区女性的筛查量降幅最大(-37.3% BC 和-26.7% CVC)。与 COVID-19 前的平均水平相比,西班牙裔女性的 BC 和 CVC 筛查量有最大的改善(BC 为 8.2%,CVC 为 9.5%),而非西班牙裔亚裔和太平洋岛裔女性的 CVC 筛查量降幅最大(-41.4% CVC)。
为了加强干预措施,NBCCEDP 的受助者可以关注筛查量降幅最大的人群。